Posted by Michael Wonder on 05 Sep 2016
EMA publishes EPAR for Zalmoxis
5 September 2016 - The EMA has published an EPAR for GSK's new cellular therapy Zalmoxis.
The European Commission conditionally approved Zalmoxis on 18 August 2016 for use as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.
Zalmoxis will be subjected to additional monitoring by the EMA.
